Analysts Set Expectations for VERV Q1 Earnings

Verve Therapeutics, Inc. (NASDAQ:VERV) – Research analysts at William Blair issued their Q1 2026 earnings estimates for shares of Verve Therapeutics in a report issued on Thursday, February 27th. William Blair analyst M. Minter anticipates that the company will post earnings per share of ($0.77) for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Verve Therapeutics’ current full-year earnings is ($2.49) per share. William Blair also issued estimates for Verve Therapeutics’ Q2 2026 earnings at ($0.74) EPS, Q3 2026 earnings at ($0.75) EPS and Q4 2026 earnings at ($0.77) EPS.

A number of other equities analysts have also recently weighed in on VERV. Royal Bank of Canada lowered their price objective on shares of Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating for the company in a research report on Tuesday. HC Wainwright increased their price objective on shares of Verve Therapeutics from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Finally, Canaccord Genuity Group increased their price objective on shares of Verve Therapeutics from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Verve Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $25.50.

Verve Therapeutics Stock Performance

NASDAQ:VERV opened at $6.12 on Monday. The stock has a market capitalization of $518.14 million, a P/E ratio of -2.49 and a beta of 1.74. The company has a 50 day moving average price of $6.92 and a 200 day moving average price of $6.04. Verve Therapeutics has a fifty-two week low of $4.30 and a fifty-two week high of $16.05.

Verve Therapeutics (NASDAQ:VERV) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.58) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.14. The firm had revenue of $13.08 million during the quarter, compared to analysts’ expectations of $3.94 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%.

Hedge Funds Weigh In On Verve Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC boosted its position in Verve Therapeutics by 189.7% in the 4th quarter. GAMMA Investing LLC now owns 6,054 shares of the company’s stock valued at $34,000 after buying an additional 3,964 shares during the period. IFP Advisors Inc raised its holdings in shares of Verve Therapeutics by 823,700.0% in the 4th quarter. IFP Advisors Inc now owns 8,238 shares of the company’s stock valued at $47,000 after purchasing an additional 8,237 shares in the last quarter. Creative Planning acquired a new stake in shares of Verve Therapeutics in the 3rd quarter valued at $50,000. BNP Paribas Financial Markets acquired a new stake in shares of Verve Therapeutics in the 4th quarter valued at $50,000. Finally, Erste Asset Management GmbH acquired a new stake in shares of Verve Therapeutics in the 3rd quarter valued at $56,000. Hedge funds and other institutional investors own 97.11% of the company’s stock.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.